HER2 Subtype Offers Clues for Individualizing Breast Cancer Care

HER2 Subtype Offers Clues for Individualizing Breast Cancer Care

One-third of patients previously identified as having HER2-positive breast cancer were found to also have a luminal subtype that was resistant to chemotherapy and trastuzumab but still sensitive to the triplet neoadjuvant regimen of pertuzumab

(Visited 1 times, 1 visits today)
3
Like
Save

Comments

Comments are disabled for this post.